Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA)

详细信息    查看全文

• 作者：Sung-Hyun Moon ; MS^a ; ^b ; Bo Yeun Yang ; PhD^a ; Young Ju Kim ; BS^a ; ^c ; Mee Kyung Hong ; MS^a ; ^c ; Yun-Sang Lee ; PhD^a ; Dong Soo Lee ; MD ; PhD^a ; June-Key Chung ; MD ; PhD^a ; ^b ; ^c ; Jae Min Jeong ; PhD^a ; ^b ; ^c ; ^{jmjng@snu.ac.kr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Encapsulation ; GUL ; Prostate cancer ; Multi-modal ; Gallium-68
• 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：12
• 期：4
• 页码：871-879
• 全文大小：1166 K

文摘

We tried to develop a dual-modal PET/MR imaging probe using a straightforward one-pot method by encapsulation with specific amphiphiles. In this study, iron oxide (IO) nanoparticles were encapsulated with three amphiphiles containing PEG, DOTA and the prostate-specific membrane antigen (PSMA)-targeting ligand in aqueous medium. The diameter of the prepared nanoparticle DOTA-IO-GUL was 11.01 ± 1.54 nm. DOTA-IO-GUL was labeled with ⁶⁸Ga in high efficiency. The DOTA-IO-GUL showed a dose-dependent binding to LNCaP (PSMA positive) cells via a competitive binding study against ¹²⁵I-labeled MIP-1072 (PSMA-targeting agent). Additionally, PET and MR imaging results showed PSMA selective uptake by only 22Rv1 (PSMA positive) but not PC-3 (PSMA negative) in dual-tumor xenograft mouse model study. MR imaging showed high resolution, and PET imaging enabled quantification and confirmation of the specificity. In conclusion, we have successfully developed the specific PSMA-targeting IO nanoparticle, DOTA-IO-GUL, as a dual-modality probe for complementary PET/MR imaging.

From the Clinical Editor

The combination of using Positron Emission Tomography (PET) and computed tomography (CT) in clinical practice is now the norm. With advances in technology, the next step would be to develop combined PET and Magnetic Resonance (MR) dual-imaging. In this article, the authors described their positive study on the development of a dual-modal PET/MR imaging probe using a prostate cancer model.